Fig. 1
Autophagy maintains Hippo/Yap pathway in liver. a Control (Atg7F/F) and Atg7 KO mice (Alb-CRE:Atg7F/F) were analyzed at 3 months (n = 4) and 12 months of age (n = 6 and 7 respectively). b Immunostaining for HNF4α in control and Atg7 KO mice. c Gene expression array analysis of whole liver RNA from controls and Atg7 KO animals. Data indicate row z-scores. d Immunostaining for Epcam in control and Atg7 KO mice. e Immunostaining for Yap in control and Atg7 KO liver sections at 3 months and 12 months. Tu, tumor. f Gene set enrichment analysis for enrichment of Hippo/Yap gene signatures and plotting of NES scores. NOM P-value *P < 0.05, **P = 0.001, ****P < 0.0001. NES, normalized enrichment score. g Gene expression array analysis of whole liver RNA from controls and Atg7 KO for Yap downstream targets. Data indicate row-z scores. h qRT-PCR analysis of whole liver RNA from control and Atg7 KO mice at 3 months for Yap downstream targets. Data normalized to Gapdh mRNA expression and expression in control mice. Data represent two independent experiments. Mean ± SD. **P < 0.01, ***P < 0.001 by two tailed t-test. i Tamoxifen (TAM)-inducible, hepatocyte-specific Atg7 KO (ERT2-Alb-CRE:Atg7F/F) and respective controls were analyzed 7, 14, and 28 days after TAM injection. j Immunoblotting of whole liver lysates from control and Atg7 KO mice, 7, 14, and 28 days after tamoxifen injection. k Quantitative band densitometry of Yap and β-tubulin immunoblots normalized to Yap/β-tubulin ratios in control mice. **P < 0.005 by two tailed t-test compared to controls. l Band densitometry of P-Yap and Yap immunoblots normalized to P-Yap/Yap ratios in control mice. **P < 0.005 and *P < 0.05 by two tailed t-test compared to controls. Scale bar 100 µm. Insets in b, d, e in the lower right corners correspond to small boxes within the associated lower magnification images
